United States - English - NLM (National Library of Medicine)

taleos pharma - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanoco - ascorbic acid 60 mg - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

square pharmaceuticals plc, (chemical division) - ascorbic acid + folic acid + iron + nicotinamide + pyridoxine hydrochloride + riboflavin + thiamine + zinc sulphate - pellets - 99.77 gm + 1.56 gm + 101.14 gm + 20.64 gm + 2.06 gm + 4.13 gm + 4.13 gm + 143.38 gm

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), lactic acid, l- (unii: f9s9ffu82n) (lactic acid, l- - unii:f9s9ffu82n), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), acetaldehyde (unii: go1n1zpr3b) (acetaldehyde - unii:go1n1zpr3b), prasterone (unii: 459ag36t1b) (prasterone - unii:459ag36t1b), phlorizin (unii: cu9s17 - ascorbic acid 6 [hp_x] in 1 ml - for temporary relief of symptoms related to high blood sugar including dry mouth, thirst, night sweats, sugar and carb cravings.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to high blood sugar including dry mouth, thirst, night sweats, sugar and carb cravings.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

deseret biologicals, inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cysteine (unii: k848jz4886) (cysteine - unii:k848jz4886), manganese gluconate (unii: 9yy2f980sv) (manganese cation (2+) - unii:h6ep7w5457), oxogluric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), fumaric acid (unii: 88xhz13131) (fumaric acid - unii:88xhz13131), germanium sesquioxide (unii: 96we91n25t) (germanium sesquioxide - unii:96we91n25t), iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4), magnesium (u - ascorbic acid 6 [hp_x] in 1 ml - for the temporary relief of symptoms related to headache, joint pain, sweating, congestion, and fatigue.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to headache, joint pain, sweating, congestion, and fatigue.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

United States - English - NLM (National Library of Medicine)

mcguff pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 500 mg in 1 ml - ascor is vitamin c indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. limitations of use ascor is not indicated for treatment of vitamin c deficiency that is not associated with signs and symptoms of scurvy. none. use in specific populations 8.1 pregnancy 8.2 lactation 8.4 pediatric use 8.5 geriatric use 8.6 renal impairment 8.1 pregnancy risk summary there are no available data on use of ascor in pregnant women to inform a drug-associated risk of adverse developmental outcomes; however, use of ascorbic acid (vitamin c) has been used during pregnancy for several decades and no adverse developmental outcomes are reported in the published literature [see data]. there are dose adjustments for ascorbic acid (vitamin c) use during pregnancy [ see clinical considerations ]. animal reproduction studies have not been conducted with ascor. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations dose adjustments during pregnancy and post-partum period follow the u.s. recommended dietary allowances (rda) for pregnant women when considering use of ascor for treatment of scurvy [ see dosage and administration (2.3 )]. data human data there are no available data on use of ascor or another ascorbic acid injection in pregnant women. however, a published meta–analysis of randomized studies evaluating a large number of pregnant women who took oral ascorbic acid (vitamin c) (through diet and supplementation) at doses ranging from 500 to1000 mg/day (2.5 to 5 times the recommended daily intravenous dose, respectively) [ see dosage and administration (2.3) ] between the 9th and 16th weeks of pregnancy showed no increased risk of adverse pregnancy outcomes such as miscarriage, preterm premature rupture of membranes, preterm delivery or pregnancy induced hypertension when compared to placebo. these data cannot definitely establish or exclude the absence of a risk with ascorbic acid (vitamin c) during pregnancy. 8.2 lactation risk summary there are no data on the presence of ascorbic acid (vitamin c) in human milk following intravenous dosing in lactating women. ascorbic acid (vitamin c) is present in human milk after maternal oral intake. maternal oral intake of ascorbic acid (vitamin c) exceeding the u.s. recommended dietary allowances (rda) for lactation does not influence the ascorbic acid (vitamin c) content in breast milk or the estimated daily amount received by breastfed infants. there are no data on the effect of ascorbic acid (vitamin c) on milk production or the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ascor and any potential adverse effects on the breastfed child from ascor or from the underlying maternal condition. follow the u.s. recommended dietary allowances (rda) for lactating women when considering use of ascor for treatment of scurvy [see dosage and administration (2.3) ]. 8.4 pediatric use ascor is indicated for the short term (up to 1 week) treatment of scurvy in pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. the safety profile of ascorbic acid in pediatric patients is similar to adults; however, pediatric patients less than 2 years of age may be at higher risk of oxalate nephropathy following ascorbic acid administration due to age-related decreased glomerular filtration [ see warnings and precautions (5.1 )]. ascor is not indicated for use in pediatric patients less than 5 months of age. 8.5 geriatric use glomerular filtration rate is known to decrease with age and as such may increase risk for oxalate nephropathy following ascorbic acid administration in elderly population [ see warnings and precautions (5.1 ) ]. 8.6 renal impairment ascor should be used with caution in scorbutic patients with a history of or risk of developing renal oxalate stones or evidence of renal impairment or other issues (e.g., patients on dialysis, patients with diabetic nephropathy, and renal transplant recipients). these patients may be at increased risk of developing acute or chronic oxalate nephropathy following high dose ascorbic acid administration [ see warning and precaution (5.1 ].

United States - English - NLM (National Library of Medicine)

trigen laboratories, inc. - omega-3 fatty acids (unii: 71m78end5s) (omega-3 fatty acids - unii:71m78end5s), linoleic acid (unii: 9kjl21t0qj) (linoleic acid - unii:9kjl21t0qj), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2 - omega-3 fatty acids 330 mg - ultimatecare one is indicated to provide vitamin/mineral and omega-3 fatty acid supplementation throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years. it is also useful for improving nutritional status prior to conception. this product is contraindicated in patients with known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

avion pharmaceuticals, llc - biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), ferrous asparto glycinate (unii: h7426rgb3l) (ferrous cation - unii:gw89581owr), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), potassium iodide (unii: 1c4qk22f9j) (iodide ion - unii:09g4i6v86q), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), doconexent (unii: zad9okh9jc) (doconexent - unii:zad9okh9jc), lowbush blueberry (unii: g90px41vp0) (icosapent - unii:aan7qov9ea), levomefolic acid (unii: 8s95dh25xc) (levomefolic acid - unii:8s95dh25xc), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - ascorbic acid 60 mg - indications: prenate mini ® is a multivitamin/multimineral fatty acid dietary supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and nonlactating mothers. prenatemini ® can also be beneficial in improving the nutritional status of women prior to conception. contraindications: prenate mini ® is contraindicated in patients with a known hypersensitivity to any of the ingredients.

Philippines - English - FDA (Food And Drug Administration)

wert philippines, inc.; importer:  ; distributor:   - ascorbic acid , zinc - chewable tablet - formulation: each tablet contains: ascorbic acid ascorbic acid (equivalent to 225 mg sodium ascorbate) zinc (equivalent to 13.75mg of zinc sulfate monohydrate) 50mg 200mg 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - ascorbic acid - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - ascorbic acid - oral tablet - 500mg